231 related articles for article (PubMed ID: 24445837)
1. Management of latent tuberculosis infection in child contacts of multidrug-resistant tuberculosis.
Adler-Shohet FC; Low J; Carson M; Girma H; Singh J
Pediatr Infect Dis J; 2014 Jun; 33(6):664-6. PubMed ID: 24445837
[TBL] [Abstract][Full Text] [Related]
2. Drug-Induced Fulminant Hepatitis in a Child Treated for Latent Multidrug-Resistant Tuberculosis With Dual Therapy Combining Pyrazinamide and Levofloxacin.
Huguet A; Ader F; Ohlmann C; Collardeau-Frachon S; Gillet Y
Pediatr Infect Dis J; 2019 Oct; 38(10):1025-1026. PubMed ID: 31335574
[TBL] [Abstract][Full Text] [Related]
3. Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis.
Papastavros T; Dolovich LR; Holbrook A; Whitehead L; Loeb M
CMAJ; 2002 Jul; 167(2):131-6. PubMed ID: 12160118
[TBL] [Abstract][Full Text] [Related]
4. Toxicity and tolerability of fluoroquinolone-based preventive therapy for childhood contacts of multidrug-resistant tuberculosis.
Seddon JA; Garcia-Prats AJ; Kampmann B; Schaaf HS; Hesseling AC
Pediatr Infect Dis J; 2014 Oct; 33(10):1098-9. PubMed ID: 25361192
[No Abstract] [Full Text] [Related]
5. Reply: To PMID 24445837.
Adler-Shohet FC; Low J; Carson M; Girma H; Singh J
Pediatr Infect Dis J; 2014 Oct; 33(10):1099-100. PubMed ID: 25361193
[No Abstract] [Full Text] [Related]
6. Latent tuberculous infection prevalence among paediatric contacts of drug-resistant and drug-susceptible cases.
Laniado-Laborín R; Cazares-Adame R; Volker-Soberanes ML; del Portillo-Mustieles C; Villa-Rosas C; Oceguera-Palao L; Magallanes-Mijares J
Int J Tuberc Lung Dis; 2014 May; 18(5):515-9. PubMed ID: 24903785
[TBL] [Abstract][Full Text] [Related]
7. [Children exposed to multidrug-resistant tuberculosis: How should we manage? Analysis of 46 child contacts and review of the literature].
Catho G; Sénéchal A; Ronnaux-Baron AS; Valour F; Perpoint T; Bouaziz A; Dumitriescu O; Reix P; Pedone C; Ader F;
Rev Pneumol Clin; 2015 Dec; 71(6):335-41. PubMed ID: 26195117
[TBL] [Abstract][Full Text] [Related]
8. Failure of chemoprophylaxis with standard antituberculosis agents in child contacts of multidrug-resistant tuberculosis cases.
Sneag DB; Schaaf HS; Cotton MF; Zar HJ
Pediatr Infect Dis J; 2007 Dec; 26(12):1142-6. PubMed ID: 18043453
[TBL] [Abstract][Full Text] [Related]
9. Multidrug-resistant tuberculosis in military recruits.
Freier G; Wright A; Nelson G; Brenner E; Mase S; Tasker S; Matthews KL; Bohnker BK
Emerg Infect Dis; 2006 May; 12(5):760-2. PubMed ID: 16704832
[TBL] [Abstract][Full Text] [Related]
10. Treatment for LTBI in contacts of MDR-TB patients, Federated States of Micronesia, 2009-2012.
Bamrah S; Brostrom R; Dorina F; Setik L; Song R; Kawamura LM; Heetderks A; Mase S
Int J Tuberc Lung Dis; 2014 Aug; 18(8):912-8. PubMed ID: 25199004
[TBL] [Abstract][Full Text] [Related]
11. Comparative roles of moxifloxacin and levofloxacin in the treatment of pulmonary multidrug-resistant tuberculosis: a retrospective study.
Jiang RH; Xu HB; Li L
Int J Antimicrob Agents; 2013 Jul; 42(1):36-41. PubMed ID: 23582696
[TBL] [Abstract][Full Text] [Related]
12. Present-day treatment of tuberculosis and latent tuberculosis infection.
Pérez-Camacho I; Rivero-Juárez A; Kindelán JM; Rivero A
Enferm Infecc Microbiol Clin; 2011 Mar; 29 Suppl 1():41-6. PubMed ID: 21420566
[TBL] [Abstract][Full Text] [Related]
13. Two-month regimen of isoniazid, rifampin and pirazinamid for latent tuberculosis infection.
Duarte R; Carvalho A; Correia A
Public Health; 2012 Sep; 126(9):760-2. PubMed ID: 22633080
[No Abstract] [Full Text] [Related]
14. [Tuberculosis].
Liippo K
Duodecim; 2010; 126(1):65-73. PubMed ID: 20405610
[TBL] [Abstract][Full Text] [Related]
15. Opportunities afforded by new drugs for tuberculosis.
Churchyard GJ; Friedland G; Fielding K; Nardell E
Lancet Infect Dis; 2010 Jun; 10(6):368-9. PubMed ID: 20510274
[No Abstract] [Full Text] [Related]
16. Fluoroquinolone and pyrazinamide resistance in multidrug-resistant tuberculosis.
Pierre-Audigier C; Surcouf C; Cadet-Daniel V; Namouchi A; Heng S; Murray A; Guillard B; Gicquel B
Int J Tuberc Lung Dis; 2012 Feb; 16(2):221-3, i-ii. PubMed ID: 22236923
[TBL] [Abstract][Full Text] [Related]
17. Systematic Review, Meta-analysis, and Cost-effectiveness of Treatment of Latent Tuberculosis to Reduce Progression to Multidrug-Resistant Tuberculosis.
Marks SM; Mase SR; Morris SB
Clin Infect Dis; 2017 Jun; 64(12):1670-1677. PubMed ID: 28329197
[TBL] [Abstract][Full Text] [Related]
18. Clinical and Cardiac Safety of Long-term Levofloxacin in Children Treated for Multidrug-resistant Tuberculosis.
Garcia-Prats AJ; Draper HR; Finlayson H; Winckler J; Burger A; Fourie B; Thee S; Hesseling AC; Schaaf HS
Clin Infect Dis; 2018 Nov; 67(11):1777-1780. PubMed ID: 29788331
[TBL] [Abstract][Full Text] [Related]
19. Levofloxacin versus placebo for the treatment of latent tuberculosis among contacts of patients with multidrug-resistant tuberculosis (the VQUIN MDR trial): a protocol for a randomised controlled trial.
Fox GJ; Nguyen CB; Nguyen TA; Tran PT; Marais BJ; Graham SM; Nguyen BH; Velen K; Dowdy DW; Mason P; Britton WJ; Behr MA; Benedetti A; Menzies D; Nguyen VN; Marks GB
BMJ Open; 2020 Jan; 10(1):e033945. PubMed ID: 31900274
[TBL] [Abstract][Full Text] [Related]
20. Limited tolerability of levofloxacin and pyrazinamide for multidrug-resistant tuberculosis prophylaxis in a solid organ transplant population.
Lou HX; Shullo MA; McKaveney TP
Pharmacotherapy; 2002 Jun; 22(6):701-4. PubMed ID: 12066961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
